Development of a blood-based biomarker concept for screening of CRC
Every year 4,250 Danes are diagnosed with primary colorectal cancer (CRC). Due to lack of evident symptoms, more than half of these do have disseminated disease at the time of diagnosis. Thereby, complete and effective treatment is far from always achievable. Currently, screening based on an immunological test for occult human blood in feces (the FIT test) has been implemented to improve the overall prognosis and reduce the incidence of the disease. At present the compliance in FIT-screening in Denmark is 64%, and the sensitivity of the FIT-test is 75%—this leads to a clinical sensitivity of 48%. Long story short: 52% of the those, who in the screen relevant population may have a neoplastic bowel lesion will not be identified.
The present colorectal cancer research includes development of a screening concept based on biological markers in blood samples. Compared to the FIT-test, current achieved results show that a blood-based screening test may be as effective in identifying subjects to be offered screen colonoscopy and— as more subjects will participate in screening—improve compliance.
Click and watch the video on how you may contribute to our research.
is our largest ever—and the definitely final evaluation of our research towards a screening model for colorectal cancer based on blood samples.
Endoscopy III-Part I is now completed and ran parallel to the public, general screening for colorectal cancer from 2014 to 2016.
Part II runs until the summer 2022.
The project is a collaboration between screening centers at 10 hospitals in Denmark—
4 in the Capital Region and 6 in the Region Middle Jutland.
The project is managed from Hvidovre Hospital.
Is a screening based on (1) a feces test + (2) a blood test + (3) a decision on colonoscopy (= complete bowel examination) or not.
25% of the current colonoscopies─following a screening based on a stool sample─can be avoided. This would benefit our socio-economics and the individual who avoids unnecessary colonoscopy.
TRIAGE in colorectal-screening is tested at 4 hospitals in the Capital Region of Copenhagen parallel to the general screening for colorectal cancer, which tests for occult blood in the stool.
Research focusing on analyses of feces-, blood- and tissue samples to identify a causal relationship between fecal bacterial, viral and fungi DNA and mutations in epithelial bowel cells and subsequent development of CRC.
Research in early detection of large bowel neoplasia based on development of a screening concept based on biological markers in blood samples.
Research in development of a blood-based test of biological markers to detect recurrence at an early stage. Early detection is urgent to offer renewed options for curative treatments.
Collaborative research including preanalytical, analytical and post-analytical issues—a validation of materials, databases, and audit issues.
Our current project—Endoskopi III─is comprised of two main work phases:
The collection of blood samples, data and records are carried out by the screening centers at 10 cooperating hospitals in Denmark:
The analyses of all the blood samples and all statistical calculations are carried out by our contractually-based collaborations with national and international biotech companies as well as leading Danish, American and European research institutions and hospitals:
Biological markers in blood identify subjects at risk of developing subsequent cancer diseases
Our basic hypothesis is confirmed as we have now shown that:
elevated levels of one or more of four biological blood markers relate to increased risk of developing a cancer disease within few years.
Application of research results:
Triage in screening for colorectal cancer—a pilot project
Using a feces test + a blood test in screening for colorectal cancer, 25% of the colonoscopies following the general screening for colorectal cancer (based on occult blood in stool samples) could be saved—and the individual avoid unnecessary colonoscopy.
The results from the pilot-project could be implemented in the current screening in DK for colorectalcancer as soon as 2018.
Read: The publication on the basic research results / published 08.03.2017
A blood test can reveal colorectal cancer.
Danish researchers are close to having developed a method for diagnosis of colorectal cancer from a blood test. Can be broadened to include all forms of cancer, says researcher. (Ref: Videnskab.dk)
Cancer Researchers want your blood instead of your stool